# VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial

> **NCT07514832** · PHASE2 · RECRUITING · sponsor: **Beijing 302 Hospital** · enrollment: 48 (estimated)

## Conditions studied

- AML (Acute Myeloid Leukemia)

## Interventions

- **DRUG:** Venetoclax, Azacitidine, Cytarabine, Idarubicin, G-CSF

## Key facts

- **NCT ID:** NCT07514832
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07514832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07514832, "VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07514832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*